Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 40.92% is in line with its 5-year average of 37.59%, near the high end of its 5-year range (29.78%–42.71%).
1.44% above its 12-month average of 40.34%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 41.17%.
EBITDA MARGIN
40.92%
EBITDA MARGIN AVG TTM
40.34%
EBITDA MARGIN AVG 3Y
39.84%
EBITDA MARGIN AVG 5Y
37.59%
EBITDA MARGIN AVG 10Y
34.05%
EBITDA MARGIN AVG 15Y
32.43%
EBITDA MARGIN AVG 20Y
30.37%
CURRENT VS TTM AVG
+1.44%
CURRENT VS 3Y AVG
+2.71%
CURRENT VS 5Y AVG
+8.87%
CURRENT VS 10Y AVG
+20.18%
CURRENT VS 15Y AVG
+26.19%
CURRENT VS 20Y AVG
+34.75%
Market Cap
$242.75B
EBITDA Margin
24.44%
TTM Avg
24.78%
3Y Avg
25.35%
5Y Avg
27.67%
Market Cap
$332.18B
EBITDA Margin
34.51%
TTM Avg
30.75%
3Y Avg
31.14%
5Y Avg
33.13%
Market Cap
$338.13B
EBITDA Margin
5.21%
TTM Avg
7.15%
3Y Avg
8.47%
5Y Avg
8.86%
Market Cap
$356.05B
EBITDA Margin
45.17%
TTM Avg
41.84%
3Y Avg
33.12%
5Y Avg
31.32%
Market Cap
$179.66B
EBITDA Margin
49.12%
TTM Avg
32.26%
3Y Avg
34.27%
5Y Avg
33.90%
Market Cap
$168.54B
EBITDA Margin
24.35%
TTM Avg
24.15%
3Y Avg
24.77%
5Y Avg
25.59%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novartis AG (NVS) | $267.96B | 40.92% | 40.34% | 39.84% | 37.59% |
| AstraZeneca PLC (AZN)vs › | $243.44B | 33.16% | 30.52% | 27.50% | 25.68% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $242.75B | 24.44% | 24.78% | 25.35% | 27.67% |
| Amgen Inc. (AMGN)vs › | $217.61B | 43.12% | 40.78% | 43.34% | 44.32% |
| Roche Holding AG (RHHBY)vs › | $332.18B | 34.51% | 30.75% | 31.14% | 33.13% |
| UnitedHealth Group Incorporated (UNH)vs › | $338.13B | 5.21% | 7.15% | 8.47% | 8.86% |
| Merck & Co., Inc. (MRK)vs › | $356.05B | 45.17% | 41.84% | 33.12% | 31.32% |
| Gilead Sciences, Inc. (GILD)vs › | $179.66B | 49.12% | 32.26% | 34.27% | 33.90% |
| Abbott Laboratories (ABT)vs › | $168.54B | 24.35% | 24.15% | 24.77% | 25.59% |
| Novo Nordisk A/S (NVO)vs › | $165.79B | 48.42% | 49.59% | 48.46% | 47.82% |
Gross Margin
74.4%
EBITDA Margin
40.9%
Operating Margin
30.5%
Net Margin
22.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 41.17% |
| 2026-03-31 | 40.39% |
| 2025-12-31 | 38.03% |
| 2025-09-29 | 40.85% |
| 2025-06-30 | 41.25% |
| 2025-03-31 | 42.71% |
| 2024-12-31 | 38.04% |
| 2024-09-30 | 42.45% |
| 2024-06-30 | 40.21% |
| 2024-03-31 | 38.67% |
| 2023-12-31 | 35.41% |
| 2023-09-30 | 40.30% |
| 2023-06-30 | 38.44% |
| 2023-03-31 | 40.63% |
| 2022-12-31 | 29.78% |
| 2022-09-30 | 34.69% |
| 2022-06-30 | 30.80% |
| 2022-03-31 | 33.22% |
| 2021-12-31 | 30.18% |
| 2021-09-30 | 35.06% |
| 2021-06-30 | 37.03% |
| 2021-03-31 | 32.39% |
| 2020-12-31 | 32.70% |
| 2020-09-30 | 33.07% |
| 2020-06-30 | 34.89% |
| 2020-03-31 | 32.69% |
| 2019-12-31 | 29.57% |
| 2019-09-30 | 30.12% |
| 2019-06-30 | 30.85% |
| 2019-03-31 | 32.15% |
| 2018-12-31 | 23.84% |
| 2018-09-30 | 31.65% |
| 2018-06-30 | 31.20% |
| 2018-03-31 | 30.24% |
| 2017-12-31 | 26.88% |
| 2017-09-30 | 30.22% |
| 2017-06-30 | 29.09% |
| 2017-03-31 | 31.38% |
| 2016-12-31 | 25.03% |
| 2016-09-30 | 30.61% |
| 2016-06-30 | 28.07% |
| 2016-03-31 | 32.35% |
| 2015-12-31 | 23.45% |
| 2015-09-30 | 28.75% |
| 2015-06-30 | 29.39% |
| 2015-03-31 | 33.33% |
| 2014-12-31 | 26.76% |
| 2014-09-30 | 29.37% |
| 2014-06-30 | 31.25% |
| 2014-03-31 | 30.18% |
| 2013-12-31 | 23.64% |
| 2013-09-30 | 28.32% |
| 2013-06-30 | 31.26% |
| 2013-03-31 | 28.79% |
| 2012-12-31 | 25.42% |
| 2012-09-30 | 29.77% |
| 2012-06-30 | 29.59% |
| 2012-03-31 | 27.89% |
| 2011-12-31 | 20.60% |
| 2011-09-30 | 29.13% |
| 2011-06-30 | 31.11% |
| 2011-03-31 | 32.44% |
| 2010-12-31 | 22.28% |
| 2010-09-30 | 29.83% |
| 2010-06-30 | 30.42% |
| 2010-03-31 | 34.57% |
| 2009-12-31 | 24.54% |
| 2009-09-30 | 28.77% |
| 2009-06-30 | 27.13% |
| 2009-03-31 | 29.17% |
| 2008-12-31 | 21.56% |
| 2008-09-30 | 28.98% |
| 2008-06-30 | 28.07% |
| 2008-03-31 | 30.56% |
| 2007-12-31 | 10.74% |
| 2007-09-30 | 30.51% |
| 2007-06-30 | 29.88% |
| 2007-03-31 | 30.67% |
| 2006-12-31 | 22.70% |
| 2006-09-30 | 28.17% |
| 2006-06-30 | 30.98% |
| 2006-03-31 | 30.50% |
| 2005-12-31 | 24.31% |
| 2005-09-30 | 28.11% |
| 2005-06-30 | 27.23% |
| 2005-03-31 | 26.77% |
| 2004-12-31 | 24.35% |
| 2004-09-30 | 29.01% |
| 2004-06-30 | 30.26% |
| 2004-03-31 | 27.16% |
| 2003-12-31 | 28.75% |
| 2003-09-30 | 29.47% |
| 2003-06-30 | 28.24% |
| 2003-03-31 | 28.93% |
| 2002-09-30 | 29.37% |
